Research programme: antibody therapeutics - Innovative Targeting Solutions
Latest Information Update: 29 Jun 2016
At a glance
- Originator Innovative Targeting Solutions
- Class Antibodies
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 2 receptor agonists; Parathyroid hormone receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
- Research Cancer; HIV infections